XML 160 R77.htm IDEA: XBRL DOCUMENT v3.20.4
Segmentation of key figures (Details 1) - USD ($)
$ in Millions
 12 Months Ended
Apr. 08, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure of operating segments [line items]        
Net sales to third parties from continuing operations   $ 48,659 $ 47,445 $ 44,751
Sales to continuing and discontinued segments     53 82
Net sales from continuing operations   48,659 47,498 44,833
Other revenues   1,239 1,179 1,266
Cost of goods sold   (15,121) (14,425) (14,510)
Gross profit from continuing operations   34,777 34,252 31,589
Selling, general and administration   (14,197) (14,369) (13,717)
Research and development   (8,980) (9,402) (8,489)
Other income   1,742 2,031 1,629
Other expense   (3,190) (3,426) (2,609)
Operating income from continuing operations   10,152 9,086 8,403
Income from associated companies   673 659 6,438
Interest expense   (869) (850) (932)
Other financial income and expense   (78) 45 186
Income before taxes from continuing operations   9,878 8,940 14,095
Taxes   (1,807) (1,793) (1,295)
Net income from continuing operations   8,071 7,147 12,800
Net income/loss from discontinued operations before gain on distribution     (101) (186)
Gain on distribution of Alcon Inc. to Novartis AG shareholders $ 4,691   4,691  
Net income/loss from discontinued operations     4,590 (186)
Net income   8,071 11,737 12,614
Operating segments [member] | Innovative Medicines        
Disclosure of operating segments [line items]        
Net sales to third parties from continuing operations   39,013 37,714 34,892
Sales to continuing and discontinued segments   792 783 741
Net sales from continuing operations   39,805 38,497 35,633
Other revenues   1,018 1,092 1,188
Cost of goods sold   (10,927) (10,050) (9,870)
Gross profit from continuing operations   29,896 29,539 26,951
Selling, general and administration   (11,657) (11,617) (10,907)
Research and development   (8,118) (8,152) (7,675)
Other income   922 1,586 977
Other expense   (1,871) (2,069) (1,475)
Operating income from continuing operations   9,172 9,287 7,871
Income from associated companies   1 1 1
Operating segments [member] | Sandoz        
Disclosure of operating segments [line items]        
Net sales to third parties from continuing operations   9,646 9,731 9,859
Sales to continuing and discontinued segments   189 141 177
Net sales from continuing operations   9,835 9,872 10,036
Other revenues   53 63 62
Cost of goods sold   (5,252) (5,334) (5,530)
Gross profit from continuing operations   4,636 4,601 4,568
Selling, general and administration   (2,076) (2,218) (2,305)
Research and development   (862) (1,250) (814)
Other income   176 167 505
Other expense   (831) (749) (622)
Operating income from continuing operations   1,043 551 1,332
Income from associated companies   2 2 5
Operating segments [member] | Corporate        
Disclosure of operating segments [line items]        
Sales to continuing and discontinued segments   (981) (871) (836)
Net sales from continuing operations   (981) (871) (836)
Other revenues   168 24 16
Cost of goods sold   1,058 959 890
Gross profit from continuing operations   245 112 70
Selling, general and administration   (464) (534) (505)
Other income   644 278 147
Other expense   (488) (608) (512)
Operating income from continuing operations   (63) (752) (800)
Income from associated companies   $ 670 $ 656 $ 6,432